Site brasileiro onde você pode comprar qualidade e entrega http://farmaciabrasilrx.com/ cialis barato em todo o mundo.

Ukbiobank.ac.uk

Professor Sir Rory Collins, Chief Executive Officer & Principal Investigator
Rory Collins was appointed Principal Investigator and Chief Executive of UK Biobank in September 2005. Rory qualified in medicine at St Thomas's Hospital Medical School, University of London, in 1981 and obtained BSc in statistics from George Washington University, Washington DC in 1977 and MSc in statistics from the University of Oxford in 1983. In 1985, he became co-director, with Professor Sir Richard Peto, of the University of OxfoIn 1996 he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies (“meta-analyses”). CTSU was awarded a Queen’s Anniversary Prize for Higher and Further Education in 2006 for its research contributions to public health. In 2011, Rory was knighted for his Services to Science. Most significant publications [citation numbers at end 2011] Baigent C, Landray MJ, … Collins R; on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-92 Cholesterol Treatment Trialists’ (CTT) Collaboration. (writing committee: Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R). Efficacy and safety of intensive LDL-cholesterol-lowering therapy: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81 Antithrombotic Trialists’ (ATT) Collaboration (writing committee: Baigent C, Blackwell L, Collins R, Emberson JR, Godwin J, Peto R; Buring JE, Hennekens CH, Kearney PM, Meade TW, Patrono C, Roncaglioni MC, Zanchetti A) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60 Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M on behalf of the PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. NEJM 2009; 361: 2518-28 Prospective Studies Collaboration (writing committee: Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R). Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2008 SEARCH Study Collaborative Group (writing committee: Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R). SLCO1B1 variants and statin-induced myopathy — A genomewide study. NEJM 2008; 359: 789-99 Prospective Studies Collaboration (writing committee: Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829-39 Cholesterol Treatment Trialists’ (CTT) Collaborators (writing committee: Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Simes J, Collins R). Efficacy and safety of cholesterol-lowering treatment: meta-analysis of individual data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78. Heart Protection Study Collaborative Group (writing committee: Collins R, Armitage J, Parish S, Sleight P, Peto R). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16 Heart Protection Study Collaborative Group (writing committee: Collins R, Armitage J, Parish S, Sleight P, Peto R). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22 Prospective Studies Collaboration (writing committee: Lewington S, Clarke R, Qizilbash N, Peto R, Collins R). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13 Antithrombotic Trialists' (ATT) Collaboration (writing committee: Baigent C, Sudlow C, Collins R, Peto R). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-86 Antiplatelet Trialists' Collaboration (writing committee: Collins R, Peto R, Baigent C, Sandercock P, Dunbabin D, Warlow C). Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106 Fibrinolytic Therapy Trialists' Collaborative Group (authors: Collins R, Baigent C, Sleight P, Peto R). Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74 Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (authors: Collins R, Parish S, Sleight P, Peto R). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60

Source: http://www.ukbiobank.ac.uk/wp-content/uploads/2012/06/Collins-key-publications1.pdf

waterloowellingtondiabetes.ca

Starting Insulin What is the best insulin regimen to use? Start with qhs insulin (NPH, glargine, detemir) as it is Effective, Convenient, Easy for the patient to accept and Easier to initiate than multiple daily doses. Should oral therapy be continued? Typically, combination therapy (metormin +/- sulfonylurea) can lead to improved glucose control with less weight gain than with insu

White pages 02/05

Scientific Oral Inflammation and Diabetes Advisory Panel Maria Emanuel Ryan, DDS, PhD, Department of Oral Biology and Pathology Stony Brook University School of Dental Medicine Ray Williams, DMDChair, Department of PeriodontologyDiabetes mellitus is a chronic metabolic disordercontributing to bacterial proliferation and oralaffecting carbohydrate, fat, and protein metabolism.

Copyright © 2010-2014 Articles Finder